Chronic Myeloid Leukemia (CML) is a form of blood cancer characterized by the abnormal growth of myeloid cells. The introduction of Dasatinib drugs has marked a significant milestone in the treatment of CML. These drugs belong to the class of tyrosine kinase inhibitors and specifically target the BCR-ABL protein, which is responsible for the uncontrolled proliferation of cancerous cells.
The advancements in targeted therapies using Dasatinib have revolutionized the management of CML ... Read more
